This paper is only available as a PDF. To read, Please Download here.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).JAMA. 1995; 274: 1017-1025
- Tissue plasminogen activator for acute ischemic stroke.N Engl J Med. 1995; 333: 1581-1587
- Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type, plasminogen activator.J Neurosurg. 1987; 67: 399-405
- Tissue plasminogen activator reduces neurological damage after cerebral embolism.Science. 1985; 230: 1289-1292
- Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke.Arch Neurol. 1988; 45: 387-391
- Tissue plasminogen activator mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.Neurology. 1989; 39: 703-708
- Thrombolysis with tPA after experimental stroke.Ann Neurol. 1988; 23: 391-394
- Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits.Stroke. 1990; 21: 1589-1593
- Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.Stroke. 1991; 22: 872-876
- Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence.Cerebrovasc Brain Met Rev. 1993; 5: 1-16
- Urgent therapy for stroke: part 1. Pilot study of tissue plasminogen activator administered within 90 minutes.Stroke. 1992; 23: 632-640
- Urgent therapy for stroke: part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset.Stroke. 1992; 23: 641-645
- Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.Neurology. 1992; 42: 976-982
- Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.Stroke. 1992; 23: 646-652
- An open multicenter study of the safety and efficacy of various doses of t-PA in patients with acute stroke: a progress report.Stroke. 1990; 21 ([abstract]): 181
- Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke.Stroke. 1993; 24: 1000-1004
- Thrombolytic therapy in acute ischemic stroke: a Danish pilot study.Stroke. 1993; 24: 1439-1446
- Trials of streptokinase in severe acute ischaemic stroke.Lancet. 1995; 345: 578-579
- Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke.Lancet. 1995; 346: 1509-1514
- Termination of streptokinase in severe acute ischaemic stroke.Lancet. 1995; 345: 57
- Combined intra-arterial and intravenous tPA for stroke.Stroke. 1997; 28 (Emergeny Management of Stroke (EMS) Investigators: Atlanta, Cincinnati, Detroit, Houston, Los Angeles, Phoenix, Portland, San Diego): 273
- Thrombolytic therapy for acute ischemic stroke—summary statement.Neurology. 1996; 47 (Report of the Quality Standards Subcommittee of the American Academy of Neurology): 835-839
- Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke.Circulation. 1996; 94: 1167-1174
Article info
Identification
Copyright
© 1997 National Stroke Association. All rights reserved. Published by Elsevier Inc.
